Search academic texts

Information × Registration Number 0207U004040, 0104U003059 , R & D reports Title To investigate the blood cytokine's profile in patients with myelodisplastic syndrome and define its significance for the selection of medical strategy popup.stage_title Head Masliak Zvenyslava Volodymyrivna, Registration Date 25-01-2007 Organization LVIV RESEARCH INSTITUTE OF BLOOD PATHOLOGY AND TRANSFUSIONAL MEDICINE popup.description2 The paper presents results of general clinical as well as specialized hematological investigations of 33 patients with MDS, 17 of them with refractory anemia (RA), 5 - with refractory anemia with ringed sideroblasts (RARS), 3 - with refractory anemia with excess of blasts (RAEB), 3 - with refractory anemia with excess of blasts in transformation phase (RAEB-t) and 5 - patients with chronic myelomonocytic leukemia (CMML). Investigation of bone marrow cell karyotype was performed for 22 patients (14 men and 8 women). It was found that occurrence of chromosomal abnormalities in bone marrow cells of investigated patients with MDS made 22,7 % of cases; among them 3 patients had complex karyotype impairments. Karyotype of 9 patients (40,9 %) showed gene mutations, presented by polyploid chromosomal set. It was also revealed that in MDS patients serum TNF-alpfa level and the levels of soluble receptors TNF-RI and TNF-RII as well as VEGF in blood serum depended on the disease subtype, existence or absence ofsigns of leukemic transformations, as well as administration of cytostatic treatment. During leukemic transformation phase we revealed increase of TNF-RII level with simultaneous decrease of TNF-alpfa level, which was apparently one of the features of apoptosis impairment in persisting leukemic clones. MDS subtypes with high proliferation potential (RARS, CMML) showed high VEGF levels, which could be corrected by the available immunomodulating drugs (interferon drugs, thalidomide). Product Description popup.authors popup.nrat_date 2020-04-02 Close